Rena Therapeutics Inc.
- Biotech or pharma, therapeutic R&D
Rena Therapeutics Inc. was established in January 2015 with the aim of accelerating the practical application of the groundbreaking nucleic acid pharmaceutical technology known as Hetero Double-Stranded Nucleic Acid Technology, called Heteroduplex oligonucleotides (HDO) technology.
In February of the same year, we were granted the title of university-launched venture by Institute of Science Tokyo (formerly Tokyo Medical and Dental University).
HDO Technology is Japan’s third novel nucleic acid pharmaceutical with high universality, applicability, and scalability. It enabled, for the first time, gene control in organs other than the liver via systemic administration, which had been the major obstacle in the clinical application of nucleic acid pharmaceuticals, by conjugating ligands tailored to the target.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}